The Effect of Prethrombolytic Cyclosporine-A Injection on Clinical Outcome of Acute Anterior ST-Elevation Myocardial Infarction

The Effect of Prethrombolytic Cyclosporine-A Injection on Clinical Outcome of Acute Anterior ST-Elevation Myocardial Infarction


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: صمد غفاری باویل , بابک کاظمی اربط , مهدی طلوعی

کلمات کلیدی: Cyclosporine-A; Myocardial infarction; Preconditioning; Reperfusion injury; Thrombolysis.

نشریه: 6208 , 4 , 31 , 2012

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله بابک کاظمی اربط
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات قلب وعروق
کد مقاله 70017
عنوان فارسی مقاله The Effect of Prethrombolytic Cyclosporine-A Injection on Clinical Outcome of Acute Anterior ST-Elevation Myocardial Infarction
عنوان لاتین مقاله The Effect of Prethrombolytic Cyclosporine-A Injection on Clinical Outcome of Acute Anterior ST-Elevation Myocardial Infarction
ناشر 4
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ خیر
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Introduction: Reperfusion injury reduces the benefits of early reperfusion therapies after acute ST-elevation myocardial infarction (STEMI). Cyclosporine-A (CsA) is a potent inhibitor of opening of the mitochondrial permeability transition pore, which has been shown to play a key role in myocardial reperfusion injury. The impact of this treatment on clinical outcomes of acute STEMI remains unknown. Our aim was to investigate the clinical outcomes of using this drug in patients with acute anterior STEMI receiving thrombolytic treatment (TLT). Methods: In this double-blinded randomized clinical trial, 101 patients with acute anterior STEMI who were candidate for TLT, were enrolled and randomly assigned into treatment or control groups. Patients in the treatment group received an intravenous bolus injection of 2.5 mg/kg of CsA immediately before TLT. The patients in the control group received an equivalent volume of normal saline. Infarct size, occurrence of major arrhythmias, heart failure, left ventricular ejection fraction (LVEF), TLT-related complications, in-hospital and 6-month mortality rates were investigated. Results: There were no significant differences among the demographics, myocardial enzyme release, occurrence of major arrhythmias [9 (18%) vs. 12 (23.5%), P = 0.80], heart failure [18 (36%) vs. 19 (38.3%), P = 0.83], LVEF at first day [34.7 ± 9.9% vs. 33.5 ± 8.1%, P = 0.50] or at discharge [37.7 ± 10% vs. 36.1 ± 8.2%, P = 0.43], and in-hospital [4 (8%) vs. 6 (11.8%), P = 0.74] or 6-month mortality rates [9 (18%) vs. 10 (19.6%), P = 0.99] between the CsA vs. the control group. Conclusion: In this study, the prethrombolytic administration of CsA was not associated with a reduction in the infarct size or any improvement in clinical outcomes.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
صمد غفاری باویلاول
بابک کاظمی اربطدوم
مهدی طلوعیسوم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
(IF=2.353)The Effect of Pre-thrombolytic Cyclosporine-A Injection on Outcome of Acute Anterior ST-Elevation Myocardial Infarction.pdf1398/09/13113230دانلود